Overview

* Jazz Pharmaceuticals ( JAZZ ) Q3 revenue grows 7% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting robust operational performance

* Company narrows 2025 revenue guidance to $4.175 - $4.275 bln

Outlook

* Company narrows 2025 revenue guidance to $4.175 - $4.275 bln

* Jazz Pharmaceuticals ( JAZZ ) expects top-line data from zanidatamab trial in 4Q25

Result Drivers

* EPIDIOLEX AND XYWAV GROWTH - Epidiolex and Xywav sales saw double-digit percentage growth, driven by increased demand and lower gross to net deductions

* MODEYSO LAUNCH - Modeyso launched commercially in August 2025 with strong initial uptake, generating $11 mln in sales

* ZEPZELCA APPROVAL - Zepzelca and atezolizumab combination approved for 1L maintenance therapy in ES-SCLC, though Zepzelca sales decreased

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $1.13 $1.11

Revenue bln bln (16

Analysts

)

Q3 Beat $8.13 $5.92

Adjusted (15

EPS Analysts

)

Q3 EPS $4.08

Q3 Beat $500.65 $368.64

Adjusted mln mln (15

Net Analysts

Income )

Q3 Net $251.41

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC ( JAZZ ) is $185.00, about 25.5% above its November 4 closing price of $137.82

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)